Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James R Powell

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of the American Association of Nurse Practitioners|April 14, 2020
Transitioning to non-insulin therapy in a patient receiving high dose insulinBasem M Mishriky, Doyle M Cummings, Carlos E Mendez, et al.
Applied Nursing Research : ANR|June 2, 2018
Factors associated with physical activity in African Americans with hypertensionLinda P Bolin, Patricia B Crane, James R Powell, et al.
Diabetes, Obesity & Metabolism|June 7, 2019
Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysisBasem M Mishriky, James R Powell, Jennifer A Wittwer, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 19, 2017
Integrated Microarray-based Tools for Detection of Genomic DNA Damage and Repair MechanismsPatrick van Eijk, Yumin Teng, Mark R Bennet, et al.
Leukemia & Lymphoma|October 2, 2012
Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximabJames R Powell, Stefan Dojcinov, Louise King, et al.
Journal of Clinical Pharmacology|May 13, 2020
Should Baseline Hemoglobin A<sub>1c</sub> or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic ReviewJarrod L Uhrig, Stephanie O Page, Basem M Mishriky, et al.
Journal of the American Geriatrics Society|November 29, 2019
Impact of Intensive Blood Pressure Therapy on Concern about Falling: Longitudinal Results from the Systolic Blood Pressure Intervention Trial (SPRINT)Dan R Berlowitz, Capri Foy, Molly Conroy, et al.
Diabetes, Obesity & Metabolism|February 16, 2024
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world dataBasem M Mishriky, Doyle M Cummings, Yuanyuan Fu, et al.
Journal of the American Geriatrics Society|September 20, 2016
Hypertension Treatment and Concern About Falling: Baseline Data from the Systolic Blood Pressure Intervention TrialDan R Berlowitz, Tonya Breaux-Shropshire, Capri G Foy, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 13, 2016
Characterizing Frailty Status in the Systolic Blood Pressure Intervention TrialNicholas M Pajewski, Jeff D Williamson, William B Applegate, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of the American Association of Nurse Practitioners|April 14, 2020
Transitioning to non-insulin therapy in a patient receiving high dose insulinBasem M Mishriky, Doyle M Cummings, Carlos E Mendez, et al.
Applied Nursing Research : ANR|June 2, 2018
Factors associated with physical activity in African Americans with hypertensionLinda P Bolin, Patricia B Crane, James R Powell, et al.
Diabetes, Obesity & Metabolism|June 7, 2019
Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysisBasem M Mishriky, James R Powell, Jennifer A Wittwer, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 19, 2017
Integrated Microarray-based Tools for Detection of Genomic DNA Damage and Repair MechanismsPatrick van Eijk, Yumin Teng, Mark R Bennet, et al.
Leukemia & Lymphoma|October 2, 2012
Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximabJames R Powell, Stefan Dojcinov, Louise King, et al.
Journal of Clinical Pharmacology|May 13, 2020
Should Baseline Hemoglobin A<sub>1c</sub> or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic ReviewJarrod L Uhrig, Stephanie O Page, Basem M Mishriky, et al.
Journal of the American Geriatrics Society|November 29, 2019
Impact of Intensive Blood Pressure Therapy on Concern about Falling: Longitudinal Results from the Systolic Blood Pressure Intervention Trial (SPRINT)Dan R Berlowitz, Capri Foy, Molly Conroy, et al.
Diabetes, Obesity & Metabolism|February 16, 2024
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world dataBasem M Mishriky, Doyle M Cummings, Yuanyuan Fu, et al.
Journal of the American Geriatrics Society|September 20, 2016
Hypertension Treatment and Concern About Falling: Baseline Data from the Systolic Blood Pressure Intervention TrialDan R Berlowitz, Tonya Breaux-Shropshire, Capri G Foy, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 13, 2016
Characterizing Frailty Status in the Systolic Blood Pressure Intervention TrialNicholas M Pajewski, Jeff D Williamson, William B Applegate, et al.
Pageof 3